Evidence comparing urinary continence outcomes between robot-assisted radical prostatectomy (RARP) and laparoscopic radical prostatectomy (LRP) remains conflicting, largely due to heterogeneity in continence definitions and assessment methods. We compared continence recovery after RARP versus LRP using the 24-hour pad test (24 h-PT) and evaluated the impact of different continence definitions on reported outcomes. We analyzed a prospectively maintained database of consecutive patients undergoing RARP or LRP between 2008 and 2025 at a tertiary center. Urinary continence was assessed during the first postoperative year at predefined time points using pad-per-day (PPD) counts and the 24-hour pad test (24 h-PT). Continence recovery was analyzed using Kaplan–Meier methods, and adjusted hazard ratios were estimated using Cox proportional hazards models. A total of 1943 patients were included, of whom 42
Abstract Background Specialised Heart Failure (HF) clinics are designed to improve the implementation of guideline-directed medical therapy (GDMT). However, contemporary multicentre real-world data on patient profiles and treatment optimisation in specialised outpatient settings remain limited. Purpose To characterise the clinical profile, laboratory biomarkers, and implementation of GDMT in outpatients with HF with reduced ejection fraction (HFrEF) followed in specialized clinics, with a specific focus on sex and age-related differences. Methods This prospective national multicentre registry included 1,099 outpatients with HFrEF (left ventricular ejection fraction ≤40%). Demographic characteristics, laboratory parameters, and GDMT use were analysed, including beta-blockers, mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and renin-angiotensin system (RAS) inhibitors. Subgroup comparisons were performed according to sex and age (age ≥75 vs <75 years) using appropriate statistical tests. Results Median age was 64 years (IQR 56–72) and 27.8% were women. Median left ventricular ejection fraction was 29% (IQR 23–34). Ischaemic aetiology predominated (47.5%) and 17% had atrial fibrillation. Overall GDMT implementation was high: beta-blockers 96.2%, MRA 88.1%, and SGLT-2 inhibitors 81.4%. Regarding RAS inhibition, 44.2% received angiotensin receptor-neprilysin inhibitors, 25.3% angiotensin receptor blockers, and 21.9% angiotensin-converting enzyme inhibitors. Men showed a higher prevalence of ischaemic aetiology (56% vs 32%, p<0.001), higher creatinine (1.11 vs 0.89 mg/dL, p<0.001), and higher haemoglobin levels (14.9 vs 13.5 g/dL, p<0.001). Patients aged ≥75 years (18%) had more hypertension (78% vs 61%, p<0.001), atrial fibrillation (17% vs 10%, p=0.002), higher NT-proBNP (1,611 vs 1,065 pg/mL, p=0.003), higher creatinine (1.20 vs 1.01 mg/dL, p<0.001) and lower haemoglobin (13.7 vs 14.6 mg/dL, p<0.001). Quadruple foundational therapy was less frequent in older patients (51% vs 66%, p<0.001). Conclusions In a large national multicentre specialized HF clinic registry, GDMT implementation was high overall. Sex-related differences were mainly driven by aetiology and laboratory profile, without major disparities in therapeutic implementation. In contrast, older patients exhibited a higher comorbidity burden, worse biomarker profile, and significantly lower optimisation of quadruple therapy, highlighting a persistent therapeutic gap in this high-risk population.Table1_Sex DifferencesTable2_Age Differences
Infrarenal aortic dissection is a rare condition, and the presence of a triple lumen has been described as a marker of instability and poor prognosis. We report the case of a 56-year-old woman with infrarenal dissection and triple lumen who presented with refractory abdominal pain. Owing to hostile anatomy, conventional endografts were unsuitable. An iliac branch device was used off-label as the main body, achieving complete reconstruction and preservation of bilateral iliac flow. This case expands previous off-label applications of iliac branch devices, demonstrating feasibility in infrarenal dissection beyond aneurysmal or occlusive disease.